S/N 08/991,143

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Bianca M. Conti-Fine

Examiner: Patrick J. Nolan

Serial No.:

08/991,143

Group Art Unit: 1644

Filed:

December 16, 1997

Docket: 600.423US1

METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES

INFORMATION DISCLOSURE STATEMENT

SEP 1 3 2000?

x CPA

Assistant Commissioner for Patents

Washington, D.C. 20231

TECH CENTER 1600/2900

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

BIANCA M. CONTI-FINE

By his Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date Schein De 15, 2000

Reg. No. 39,665

Customer Number 21186

"Express Mail" mailing label number: EL576922958US

Date of Deposit: September 5, 2000 This paper or fee is being deposited on the date indicated above with the United States Postal Service pursuant to 37 CFR 1.10, and is addressed to Box CPA, Commissioner for Patents, Washington, D. C. 20231.